Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer. She will serve on the Executive Leadership team

Related Keywords

Denmark ,Toronto ,Ontario ,Canada ,Lisa Rojkjaer ,Nathalie Dubois Stringfellow ,Louise Wilkie ,Gewinn Nur ,Bettina Cockroft ,Linkedin ,Clinical Development ,Novo Nordisk ,Sangamo Therapeutics Inc ,Global Clinical Program Head At Novartis Oncology ,Twitter ,Head Of Clinical Development At Morphosys ,Global Medical Affairs ,University Of Toronto ,Nasdaq ,Exchange Commission ,Development Officer ,Sangamo Therapeutics ,Chief Medical ,Executive Leadership ,Chief Development ,Chief Development Officer ,Chief Medical Officer ,Global Clinical Program Head ,Novartis Oncology ,Molecular Partners ,Annual Report ,Quarterly Report ,Relations Media Inquiries ,Sangamo ,Herapeutics ,Nnounces ,Appointment ,Lisa ,Ojkjaer ,Chief ,Medical ,Officer ,